CN106397564B - 黑框蟾蜍抗氧化肽及其基因和在制药中的应用 - Google Patents
黑框蟾蜍抗氧化肽及其基因和在制药中的应用 Download PDFInfo
- Publication number
- CN106397564B CN106397564B CN201610917911.XA CN201610917911A CN106397564B CN 106397564 B CN106397564 B CN 106397564B CN 201610917911 A CN201610917911 A CN 201610917911A CN 106397564 B CN106397564 B CN 106397564B
- Authority
- CN
- China
- Prior art keywords
- peptide
- antioxidant
- toad
- black
- gene
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 101800000068 Antioxidant peptide Proteins 0.000 title abstract description 41
- 108090000623 proteins and genes Proteins 0.000 title abstract description 23
- 241000269370 Xenopus <genus> Species 0.000 claims abstract description 11
- 239000003001 serine protease inhibitor Substances 0.000 claims abstract description 10
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims abstract description 8
- 235000018417 cysteine Nutrition 0.000 claims abstract description 8
- 229940122055 Serine protease inhibitor Drugs 0.000 claims abstract description 5
- 101710102218 Serine protease inhibitor Proteins 0.000 claims abstract description 5
- 239000003814 drug Substances 0.000 claims description 10
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 33
- 241001415432 Duttaphrynus melanostictus Species 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 17
- 150000001413 amino acids Chemical class 0.000 abstract description 14
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 14
- 229920001184 polypeptide Polymers 0.000 abstract description 12
- 230000003064 anti-oxidating effect Effects 0.000 abstract description 11
- 239000002773 nucleotide Substances 0.000 abstract description 10
- 125000003729 nucleotide group Chemical group 0.000 abstract description 10
- 235000001014 amino acid Nutrition 0.000 abstract description 4
- 108010069514 Cyclic Peptides Proteins 0.000 abstract description 3
- 102000001189 Cyclic Peptides Human genes 0.000 abstract description 3
- 101710186708 Agglutinin Proteins 0.000 abstract description 2
- 101710146024 Horcolin Proteins 0.000 abstract description 2
- 101710189395 Lectin Proteins 0.000 abstract description 2
- 101710179758 Mannose-specific lectin Proteins 0.000 abstract description 2
- 101710150763 Mannose-specific lectin 1 Proteins 0.000 abstract description 2
- 101710150745 Mannose-specific lectin 2 Proteins 0.000 abstract description 2
- 239000000910 agglutinin Substances 0.000 abstract description 2
- 239000000243 solution Substances 0.000 description 21
- 230000003078 antioxidant effect Effects 0.000 description 19
- 239000003963 antioxidant agent Substances 0.000 description 18
- 235000006708 antioxidants Nutrition 0.000 description 18
- 239000002299 complementary DNA Substances 0.000 description 15
- 239000000203 mixture Substances 0.000 description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 238000000034 method Methods 0.000 description 10
- 239000006228 supernatant Substances 0.000 description 10
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 208000007882 Gastritis Diseases 0.000 description 8
- 206010033645 Pancreatitis Diseases 0.000 description 8
- 235000013305 food Nutrition 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 8
- 150000003254 radicals Chemical class 0.000 description 8
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 102000012479 Serine Proteases Human genes 0.000 description 6
- 108010022999 Serine Proteases Proteins 0.000 description 6
- 102000004142 Trypsin Human genes 0.000 description 6
- 108090000631 Trypsin Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 239000012588 trypsin Substances 0.000 description 6
- 206010061218 Inflammation Diseases 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 239000002537 cosmetic Substances 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 238000011160 research Methods 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 241000282414 Homo sapiens Species 0.000 description 4
- 208000018737 Parkinson disease Diseases 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000007760 free radical scavenging Effects 0.000 description 4
- 230000007062 hydrolysis Effects 0.000 description 4
- 238000006460 hydrolysis reaction Methods 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000004770 neurodegeneration Effects 0.000 description 4
- 230000003647 oxidation Effects 0.000 description 4
- 238000007254 oxidation reaction Methods 0.000 description 4
- -1 oxygen free radical Chemical class 0.000 description 4
- 230000001376 precipitating effect Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XQNRANMFRPCFFW-GCJQMDKQSA-N Ala-Thr-Asn Chemical compound C[C@H]([C@@H](C(=O)N[C@@H](CC(=O)N)C(=O)O)NC(=O)[C@H](C)N)O XQNRANMFRPCFFW-GCJQMDKQSA-N 0.000 description 3
- CYXCAHZVPFREJD-LURJTMIESA-N Arg-Gly-Gly Chemical compound NC(=N)NCCC[C@H](N)C(=O)NCC(=O)NCC(O)=O CYXCAHZVPFREJD-LURJTMIESA-N 0.000 description 3
- JJGRJMKUOYXZRA-LPEHRKFASA-N Asn-Arg-Pro Chemical compound C1C[C@@H](N(C1)C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(=O)N)N)C(=O)O JJGRJMKUOYXZRA-LPEHRKFASA-N 0.000 description 3
- 102000013585 Bombesin Human genes 0.000 description 3
- 108010051479 Bombesin Proteins 0.000 description 3
- 241000269417 Bufo Species 0.000 description 3
- 241000269420 Bufonidae Species 0.000 description 3
- AJHCSUXXECOXOY-NSHDSACASA-N Gly-Trp Chemical compound C1=CC=C2C(C[C@H](NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-NSHDSACASA-N 0.000 description 3
- LBRCLQMZAHRTLV-ZKWXMUAHSA-N Ile-Gly-Ser Chemical compound CC[C@H](C)[C@H](N)C(=O)NCC(=O)N[C@@H](CO)C(O)=O LBRCLQMZAHRTLV-ZKWXMUAHSA-N 0.000 description 3
- AJHCSUXXECOXOY-UHFFFAOYSA-N N-glycyl-L-tryptophan Natural products C1=CC=C2C(CC(NC(=O)CN)C(O)=O)=CNC2=C1 AJHCSUXXECOXOY-UHFFFAOYSA-N 0.000 description 3
- HXNYBZQLBWIADP-WDSKDSINSA-N Pro-Cys Chemical compound OC(=O)[C@H](CS)NC(=O)[C@@H]1CCCN1 HXNYBZQLBWIADP-WDSKDSINSA-N 0.000 description 3
- KVEWWQRTAVMOFT-KJEVXHAQSA-N Thr-Tyr-Val Chemical compound [H]N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](C(C)C)C(O)=O KVEWWQRTAVMOFT-KJEVXHAQSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- DNDCVAGJPBKION-DOPDSADYSA-N bombesin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CC=1NC2=CC=CC=C2C=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1NC(=O)CC1)C(C)C)C1=CN=CN1 DNDCVAGJPBKION-DOPDSADYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000003593 chromogenic compound Substances 0.000 description 3
- 238000010276 construction Methods 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 108010010096 glycyl-glycyl-tyrosine Proteins 0.000 description 3
- 108010084389 glycyltryptophan Proteins 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000035931 haemagglutination Effects 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 208000015122 neurodegenerative disease Diseases 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 230000017854 proteolysis Effects 0.000 description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 208000024827 Alzheimer disease Diseases 0.000 description 2
- PYIXHKGTJKCVBJ-UHFFFAOYSA-N Astraciceran Natural products C1OC2=CC(O)=CC=C2CC1C1=CC(OCO2)=C2C=C1OC PYIXHKGTJKCVBJ-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- NDVRQFZUJRMKKP-UHFFFAOYSA-N Betavulgarin Natural products O=C1C=2C(OC)=C3OCOC3=CC=2OC=C1C1=CC=CC=C1O NDVRQFZUJRMKKP-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108090001090 Lectins Proteins 0.000 description 2
- 102000004856 Lectins Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- IHPVFYLOGNNZLA-UHFFFAOYSA-N Phytoalexin Natural products COC1=CC=CC=C1C1OC(C=C2C(OCO2)=C2OC)=C2C(=O)C1 IHPVFYLOGNNZLA-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 2
- 206010039966 Senile dementia Diseases 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000023555 blood coagulation Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000012292 cell migration Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000002526 effect on cardiovascular system Effects 0.000 description 2
- 238000004992 fast atom bombardment mass spectroscopy Methods 0.000 description 2
- 230000020764 fibrinolysis Effects 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 108010082286 glycyl-seryl-alanine Proteins 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- 239000002523 lectin Substances 0.000 description 2
- 230000031700 light absorption Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 230000007918 pathogenicity Effects 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 150000002978 peroxides Chemical class 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 239000000280 phytoalexin Substances 0.000 description 2
- 150000001857 phytoalexin derivatives Chemical class 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000012846 protein folding Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000029865 regulation of blood pressure Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 230000032258 transport Effects 0.000 description 2
- 230000005760 tumorsuppression Effects 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 239000002699 waste material Substances 0.000 description 2
- YDMBNDUHUNWWRP-VJBWXMMDSA-N (2s)-1-[(2r)-2-amino-3-phenylpropanoyl]-n-[(2s)-5-(diaminomethylideneamino)-1-(4-nitroanilino)-1-oxopentan-2-yl]piperidine-2-carboxamide Chemical compound C([C@@H](N)C(=O)N1[C@@H](CCCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NC=1C=CC(=CC=1)[N+]([O-])=O)C1=CC=CC=C1 YDMBNDUHUNWWRP-VJBWXMMDSA-N 0.000 description 1
- OCZVHBZNPVABKX-UHFFFAOYSA-N 1,1-diphenyl-2-(2,4,6-trinitrophenyl)hydrazine;ethanol Chemical compound CCO.[O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1NN(C=1C=CC=CC=1)C1=CC=CC=C1 OCZVHBZNPVABKX-UHFFFAOYSA-N 0.000 description 1
- CWNPOQFCIIFQDM-UHFFFAOYSA-N 3-nitrobenzyl alcohol Chemical compound OCC1=CC=CC([N+]([O-])=O)=C1 CWNPOQFCIIFQDM-UHFFFAOYSA-N 0.000 description 1
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000340668 Bombina maxima Species 0.000 description 1
- 241001415440 Bufo gargarizans Species 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229940123457 Free radical scavenger Drugs 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241001573550 Hylarana Species 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 229940123541 Lectin inhibitor Drugs 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 241000544912 Melanoides Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 241000270959 Pelophylax nigromaculatus Species 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 241000270980 Rugosa rugosa Species 0.000 description 1
- 108010039286 S 2238 Proteins 0.000 description 1
- 108050000761 Serpin Proteins 0.000 description 1
- 102000008847 Serpin Human genes 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 102000001400 Tryptase Human genes 0.000 description 1
- 108060005989 Tryptase Proteins 0.000 description 1
- 241000269368 Xenopus laevis Species 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- 230000036592 analgesia Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 125000000837 carbohydrate group Chemical group 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 238000011033 desalting Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000011536 extraction buffer Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 1
- 230000000503 lectinlike effect Effects 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 238000002690 local anesthesia Methods 0.000 description 1
- 238000010841 mRNA extraction Methods 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000008557 oxygen metabolism Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 208000024335 physical disease Diseases 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000003672 processing method Methods 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 239000002516 radical scavenger Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940126585 therapeutic drug Drugs 0.000 description 1
- 230000001550 time effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 229940126672 traditional medicines Drugs 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/463—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from amphibians
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Inorganic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Dermatology (AREA)
- Birds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明涉及黑框蟾蜍抗氧化肽及其基因和在制药中的应用,所述的黑框蟾蜍抗氧化肽是由33个氨基酸组成的环肽,分子量3678.14道尔顿,等电点10.33,其氨基酸序列为如SEQ ID NO.1所示,上述多肽的其第三位半胱氨酸和第八半胱氨酸形成分子内二硫键。所述黑框蟾蜍抗氧化肽的基因序列由SEQ ID NO.4组成,其中编码有功能的成熟黑框蟾蜍抗氧化肽是第394‑492位核苷酸。本发明由黑框蟾蜍抗氧化肽的基因推导其成熟功能多肽氨基酸序列,合成的黑框蟾蜍抗氧化肽具有很强的凝集素、丝氨酸蛋白酶抑制剂活性和抗氧化作用。
Description
技术领域:
本发明涉及生物医学领域,具体涉及一种从动物组织得到的蛋白以及在生物制药中的用途。
背景技术:
生物分子的氧化是一个氧自由基介导的过程,它对食品和生物系统会造成许多不利的影响。在好氧器官内,与动脉硬化、癌症等多种疾病相关的游离自由基不可避免的随着氧代谢的过程而产生。另外,氧化应激被认为与多种疾病,例如老年痴呆症、帕金森氏症、糖尿病、类风湿性关节炎和肌萎缩性脊髓侧索硬化症引发的神经退行性变有关(FoodChemistry,2008,107,1485–1493)。在食品中,营养成分的氧化会产生过氧化物,其不仅会影响食品营养价值,造成食品品质的下降,严重的甚至还会导致摄入者的身体疾病(Journal of Food Science,1999,64,1000–1004)。因此寻找安全的抗氧化剂以抑制过氧化物产生一直是生化营养学的研究热点。由于BHT、BHA和没食子酸丙酯等化学合成抗氧化剂比天然抗氧化剂具有更好的效果和更便宜的价格,因此被广泛应用于食品行业中。但是,目前有研究发现合成抗氧化剂对人体肝、脾、肺等器官有积蓄性致癌作用,从而引起了人们对其安全性的担忧,并且开始慢慢限制其在食品中的使用,于是让人们把目光转向天然的抗氧化剂(Food Processing,1993,12,54–56)。α-生育酚是一种普遍适用的天然抗氧化剂,它能有效保持食品中油脂的稳定性,但却不利于食品保存。因此有必要寻找其他来源的天然抗氧化剂。由于两栖动物居住环境的特殊性,他们有时会受到自由氧等损害,这些活性自由氧能通过氧化脂肪、变性蛋白、破坏核酸,导致对代谢的严重后果和对组织和细胞的大量破坏。为了抵消这种氧化损害生存下来,两栖动物已经进化形成了抗氧化防御系统,抗氧化多肽是其中的一类重要组分。目前,从R.pleuraden、R.catesbeiana、O.livida等物种中鉴定了十几种具有抗氧化活性的多肽(Chem Rev.2015,115(4):1760-1846)。因此,两栖动物皮肤是天然抗氧化多肽的重要来源。能作为药物递呈的载体的凝集素已经被研究了几十年,很少从两栖动物皮肤中被鉴定,但是具有海藻糖结合活性的odorranalectin已经从O.grahami皮肤中被鉴定(PLoS One.2008,3(6):e2381),意味着两栖动物皮肤也是凝集素样肽的重要来源。
丝氨酸蛋白酶抑制剂(serine protease inhibitor,serpin)的最基本功能是防止蛋白质水解,调节丝氨酸蛋白酶的水解平衡。通过对丝氨酸蛋白酶的调节,丝氨酸蛋白酶抑制剂对生物体内的生理生化功能都有重要的影响。如,它们在血液凝固、补体形成、纤溶、蛋白质折叠、细胞迁移、细胞分化、细胞基质重建、激素形成及转运、细胞内蛋白质水解、血压调节、肿瘤抑制以及病毒或寄生虫致病性的形成等方面都有重要作用。丝氨酸蛋白酶抑制剂调节如此众多的生理过程导致它们有广泛的临床应用价值,如,抑酶肽aprotinin除在临床上广泛用于胃炎、胰腺炎等疾病的治疗外,也在胸外科手术中用于抗纤溶、抑制接触性激活、抗炎症等(Br J Anaesth.2013,110(5):675-8)。丝氨酸蛋白酶类似物如Kallikrein、tryptase在风湿性关节炎以及鼻炎、结膜炎、哮喘、胃肠炎、心血管系统炎症等炎症发生中起着重要的作用(Biol Chem.2004,385(11):989-96)。因此,丝氨酸蛋白酶抑制肽已成为国际研究的热点,其研究与开发则蕴含着巨大的临床治疗药物的制备价值。
两栖动物一直以来都是传统药物的源泉。中华蟾蜍(Bufo gargarizans),大蹼铃蟾(Bombina maxima)、黑斑蛙(pelophylax nigromaculata)、沼蛙(Hylarana guentheri)和泽蛙(Euphlyctis limnocharis)等两栖类动物被作为中国的传统中药材而被广泛的应用。现代研究表明:这些两栖动物的皮肤和内脏具有广泛的药理活性,如,广谱抗菌作用、抗肿瘤、局部麻醉、镇痛、免疫调节、对心血管系统的作用等(Dongwuxue Yanjiu,2015,36(4):183-222)。传统中药药物成分的复杂性及其炮制方法的局限性造成药物活性成分不能更好发挥作用,从这些传统药物中寻找特定的活性单体化合物是中药现代化的重要内容之一。在国外,两栖类皮肤特定药理活性单体化合物的寻找已经成为新药发明的热点。目前有许多分子量小于10kDa的蛋白酶抑已经从两栖动物皮肤中被鉴定。这些多肽包括ranacyclin-B、KPHTI、HV-BBI、HJTI、hylaserpin S2、OGTI、PYR、PSKP-1、PSKP-2、BOTI、BVTI、BMTI、BPTI、pLR和BSTI等(Chem Rev.2015,115(4):1760-1846)。
我国对两栖类药物的应用有悠久的历史,但对其活性成分和药理性质的研究主要集中于生物碱等有机小分子,对其皮肤活性肽类物质研究不多。黑框蟾蜍(Duttaphrynusmelanostictus)是我国特色资源动物之一。其耳后腺及疣粒均藏毒液可制成名贵中药“蟾酥”,可用于解毒消肿等。另外其自然蜕下的角质衣膜制成的“蟾衣”亦有药用效果。此外把黑眶蟾蜍除去内脏后加工制成的“干蟾”亦是中药材的一种。
发明人将本发明的黑框蟾蜍抗氧化肽的全序列氨基酸结构经蛋白质数据库进行搜寻比较,未发现有任何相同多肽。发明人将本发明的黑框蟾蜍抗氧化肽编码基因经基因数据库进行搜寻比较,未发现有任何相同基因。
发明内容:
本发明的目的是基于上述技术背景,提供一种新的具有凝集素、蛋白酶抑制剂活性和抗氧化作用的黑框蟾蜍抗氧化肽及其基因和它作为制备胃炎、胰腺炎药物和美容护肤品的应用。
为了解决上述技术问题,本发明采用的技术方案是:
本发明一个方面提供了一种黑框蟾蜍肽,所述多肽的序列如SEQ ID No.1所示
KPCKGWLCKLKLRGGYTLIGSATNLNRPTYVRA SEQ ID NO.1。
本发明另一个方面提供了一种黑框蟾蜍肽,其特征在于,所述黑框蟾蜍肽是由33个氨基酸组成的环肽,分子量3678.14道尔顿,等电点10.33,其氨基酸序列为:Lys Pro CysLys Gly Trp Leu Cys Lys Leu Lys Leu Arg Gly Gly Tyr Thr Leu Ile Gly Ser AlaThr Asn Leu Asn Arg Pro Thr Tyr Val Arg Ala(KPCKGWLCKLKLRGGYTLIGSATNLNRPTYVRA)(SEQ ID NO.1),其第三位半胱氨酸和第八位半胱氨酸形成分子内二硫键。
本发明再一个方面提供了黑框蟾蜍肽基因的核苷酸序列,其特征在于:cDNA由495个核苷酸组成,其自5’端至3’端序列如下SEQ ID NO.4所示
本发明再一个方面提供了一种编码权利要求1所述的黑框蟾蜍肽的核苷酸。
本发明再一个方面提供了权利要求1所述的黑框蟾蜍肽在制备病原胃炎、胰腺炎药物、神经退行性疾病和美容护肤品应用。
本发明再一个方面提供了如前所述的黑框蟾蜍肽在制备清除自由基药物或美容用品中的用途。
本发明再一个方面提供了如前所述的黑框蟾蜍肽在制备抗氧化药物或美容用品中的用途。
本发明再一个方面提供了如前所述的黑框蟾蜍肽在制备预防或治疗与胃炎或胰腺炎的药物中的用途,优选,所述胃炎或胰腺炎为炎症相关的胃炎或炎症相关的胰腺炎。
本发明再一个方面提供了如前所述的黑框蟾蜍肽在制备靶向药物载体中的用途。
本发明的有益效果在于:
由黑框蟾蜍抗氧化肽编码基因推导其氨基酸结构,合成的黑框蟾蜍抗氧化肽具有显著的凝集素、蛋白酶抑制剂活性和抗氧化作用。该黑框蟾蜍抗氧化肽具有结构简单、人工合成方便、活性强的有益特点。
附图说明:
图1为本发明黑框蟾蜍抗氧化肽HPLC纯化鉴定结果;
图2为本发明黑框蟾蜍抗氧化肽质谱鉴定结果;
图3为本发明黑框蟾蜍抗氧化肽清除DPPH和ABTS自由基的“量-效”关系曲线;
图4为本发明黑框蟾蜍抗氧化肽在不同浓度是清除ABTS自由基的“时-效”关系曲线;
图5为本发明黑框蟾蜍抗氧化肽凝集鸡血红细胞结果;
图6为本发明黑框蟾蜍抗氧化肽抑制丝氨酸蛋白酶对发色底物水解的“量-效”关系曲线;
具体实施方式:
下面结合附图和具体实施方式对本发明作进一步详细说明:
本发明的黑框蟾蜍抗氧化肽,所述的黑框蟾蜍抗氧化肽是由33个氨基酸组成的环肽,分子量3678.14道尔顿,等电点10.33,其氨基酸序列为:Lys Pro Cys Lys Gly Trp LeuCys Lys Leu Lys Leu Arg Gly Gly Tyr Thr Leu Ile Gly Ser Ala Thr Asn Leu AsnArg Pro Thr Tyr Val Arg Ala(KPCKGWLCKLKLRGGYTLIGSATNLNRPTYVRA)(SEQ ID NO.1),上述多肽的其第三位半胱氨酸和第八半胱氨酸形成分子内二硫键。
所述黑框蟾蜍抗氧化肽的基因序列SEQ ID NO.4的第394-492位核苷酸编码。本发明的黑框蟾蜍抗氧化肽及其基因的制备过程包括如下步骤:
实施例1,黑框蟾蜍抗氧化肽基因克隆:
I、黑框蟾蜍皮肤总RNA提取:活体黑框蟾蜍用水清洗干净,放入液氮中速冻4h,取皮肤组织,称重,取300mg皮肤组织,加入10m1总RNA提取缓冲液(Trizol溶液,美国GIBCOBRL公司产品),于20m1玻璃匀浆器中匀浆30min。加入等体积酚/氯仿溶液,剧烈混匀,室温放置10min,4℃,12000rpm离心10min,弃除沉淀。向上清中加入等体积的异丙醇,室温放置10min,4℃,12000rpm离心10min,沉淀用75%乙醇洗一次,晾干,管底的沉淀物即为黑框蟾蜍皮肤总RNA。
II、黑框蟾蜍皮肤mRNA的纯化:黑框蟾蜍皮肤mRNA分离纯化采用美国PROMEGA公司的mRNA Isolation Systems试剂盒。具体如下:取黑框蟾蜍皮肤总RNA 500μg溶于500μl DEPC水中,放入65℃水浴10min,加人3μl Oligo(dT)探针和13μl 20×SSC溶液,混匀,放置室温冷却,称为A液。将磁珠轻弹混匀,至磁力架吸附30S,弃上清,加0.5×SSC0.3m1,至磁力架吸附30S,最后加0.1ml 0.5×SSC悬浮,称之为B液。将A液加入B液中,室温放置10分钟,至磁力架吸附30sec,弃上清,用0.1×SSC洗涤4次,最后弃上清,加0.L mlDEPC水悬浮,至磁力架上吸附30sec,将上清移至新的试管,再加入0.15m1DEPC水重新悬浮,至磁力架吸附30S,移上清至上述试管,则上清中为纯化的黑框蟾蜍皮肤mRNA。加入1/10体积3M乙酸钠,pH5.2,等体积异丙醇,于-70℃放置30分钟,4℃,12000rpm离心10min,弃上清,沉淀溶解于10μl DEPC水中得到黑框蟾蜍皮肤mRNA。
III、黑框蟾蜍皮肤cDNA文库构建:采用CLONTECH公司CreatorTM SMART TM cDNALibrary Construction Kit质粒cDNA文库构建试剂盒。
A.cDNA第一链合成(mRNA反转录):在0.5ml无菌的离心管加入1μl黑框蟾蜍皮肤mRNA、1μl SMART IV寡聚核苷酸、1μl CDS III/3’PCR引物,加2μl去离子水使总体积达到5μl。混匀离心管中的试剂并以12000rpm离心15sec,72℃保温2min。将离心管在冰上孵育2min。在离心管中加入以下试剂2.0μl 5×第一链缓冲、1.0μl 20mM二硫苏糖醇、1.0μl10mMdNTP混合物、1.0μl PowerScript反转录酶。混合离心管中试剂并以12000rpm离心15sec,在42℃保温1h。将离心管置于冰上中止第一链的合成。从离心管取2μl所合成的cDNA第一链备用。
B.采用长末端聚合酶链式反应(LD-PCR)方法扩增第二链:95℃预热PCR仪。将2μlcDNA第一链(mRNA反转录)、80μl去离子水、10μl 10×Advantage 2PCR缓冲、2μl 50×dNTP混合物、2μl 5’PCR引物、2μl CDS III/3’PCR引物以及2μl大肠杆菌聚合酶离心管进行反应。在PCR仪中按以下程序扩增:95℃20sec,95℃5sec,68℃6min,22个循环。循环结束后,将离心管中合成的cDNA双链进行抽提。
C.PCR产物用PROMEGA公司的SV Gel and PCR Clean-Up System试剂盒进行抽提回收,步骤如下:将通过PCR得到的cDNA双链加入等体积的膜结合缓冲颠倒混匀,然后将混和液转入离心纯化柱,室温静置5分钟,使DNA充分与硅胶膜结合。以12000rpm离心30sec,倒掉收集管中的废液。加入700μl的洗脱液(含乙醇)于离心纯化柱中,以12000rpm离心30sec,倒掉收集管中的废液。重复步骤上述步骤。12000rpm离心5min。将离心纯化柱置于新的离心管中。加入30μl超纯水,在室温下静置5min。以12000rpm离心30sec,管底溶液即为所纯化过的cDNA双链。
D.酶切、连接以及连接产物的转化:在微量离心管中加入1μl Takara pMD18-T载体、4μl黑框蟾蜍cDNA双链溶液,全量为5μl。加入5μl的连接酶缓冲混合物。16℃反应2h。全量(10μl)加入至100μl DH5α感受态细胞中,冰中放置30min。42℃加热90Sec后,再在冰中放置1分钟。加入37℃孵育过的LB培养基890μl,37℃缓慢振荡培养60min。取200μl涂布于含有X-Gal、IPTG、Amp的LB培养基上37℃培养16h,形成单菌落。每个LB平皿用5m1LB液体培养基洗涤菌落,加30%甘油冻存。构建的cDNA大约含1×106个单独克隆。
Ⅳ、黑框蟾蜍抗氧化肽基因克隆筛选:扩增引物长度为24个核苷酸,其序列为5’ATGAGGAGCTGGAGGCTGTCTCTG 3’(SEQ ID NO.2),PCR另一扩增引物为CLONTECH公司SMARTTMcDNA Library Construction Kit中的3’PCR Primer引物,其序列为5’ATTCTAGAGGCCGAGGCGGCCGACATG 3’(SEQ ID NO.3)。PCR反应在如下条件下进行:94℃30sec,50℃45sec和72℃2.5min,35个循环。
首先滴定构建的细菌cDNA文库,然后用含100μg/ml氨苄青霉素的LB培养基稀释至适当的细菌浓度(大约5000个细菌/毫升和30个细菌/毫升分别用于首轮筛选第二轮筛选),在96孔培养板上按8×8矩阵铺板(共64孔,每孔100μ1),37℃过夜培养。按行、列分别合并细菌培养液,有16个样品进行PCR鉴定,交叉阳性孔细菌样品进入第二轮筛选。
Ⅴ、黑框蟾蜍抗氧化肽基因序列测定和结果:提取质粒DNA用双脱氧法测定核苷酸序列,使用仪器为美国Applied Biosystems 373A全自动核苷酸序列测定仪,测序引物为BcaBESTTM Sequencing Primer RV-M和BcaBESTTM Sequencing Primer M13-47,BcaBESTTMSequencing Primer RV-M序列:5`GAGCGGATAACAATTTCACACAGG 3’(SEQ ID NO.5),BcaBESTTM Sequencing Primer M13-47:5’CGCCAGGGTTTTCCCAGTCACGAC 3’(SEQ IDNO.6)。基因测序结果自5’端至3’端序列为(SEQ ID NO.4):
黑框蟾蜍抗氧化肽基因核苷酸的序列表为:序列长度为359个碱基;序列类型:核酸;链数:单链;拓扑学:直链状;序列种类:cDNA;来源:黑框蟾蜍皮肤。
根据黑框蟾蜍抗氧化肽的基因推断编码具有功能的成熟肽为第394-492位核苷酸,氨基酸序列为:KPCKGWLCKLKLRGGYTLIGSATNLNRPTYVRA(见序列SEQ ID NO.1)
实施例2,黑框蟾蜍抗氧化肽的制备:
Ⅰ、黑框蟾蜍抗氧化肽的制备方法:根据黑框蟾蜍抗氧化肽的基因推断编码由功能的成熟活分泌肽氨基酸序列后用自动多肽合成仪合成多肽。二硫键的形成采用空气氧化法,具体为在烧瓶中将多肽溶解按照0.1mg/ml于0.1%醋酸溶液中后用氢氧化铵滴定成pH7.8,然后室温搅拌过夜。通过HPLC反相C18柱层析脱盐、纯化。纯化时A液体为0.05%TFA+2%CH3CN,B液为0.05%TFA+90%CH3CN,B液浓度梯度15min为20-40%,检测波长为220nm,多肽出现在11.670分钟。
Ⅱ、分子量测定采用快原子轰击质谱法(Fast atom bombardment massspectrometry,FAB-MS),以甘油:间硝基苄醇:二甲亚砜(1:1:l,V:V:V,体积比)为底物,Cs+作为轰击粒子,电流为1μA,发射电压为25Kv。
Ⅲ、纯化的黑框蟾蜍抗氧化肽用高效液相色谱(HPLC)方法鉴定其纯度,等电聚焦电泳测定等电点,用自动氨基酸测序仪测定氨基酸序列结构。
黑框蟾蜍抗氧化肽是中国两栖类动物黑框蟾蜍抗氧化肽基因编码的一种环状多肽,分子量3678.14道尔顿,等电点10.33,其氨基酸序列为:Lys Pro Cys Lys Gly Trp LeuCys Lys Leu Lys Leu Arg Gly Gly Tyr Thr Leu Ile Gly Ser Ala Thr Asn Leu AsnArg Pro Thr Tyr Val Arg Ala(KPCKGWLCKLKLRGGYTLIGSATNLNRPTYVRA)(SEQ ID NO.1),上述多肽的第三位半胱氨酸和第八位半胱氨酸形成分子内二硫键使多肽成环。
实施例3,黑框蟾蜍抗氧化肽的活性实验
Ⅰ、抗氧化能力测定
1)DPPH自由基清除能力的测定
利用DPPH(1,1-diphenyl-2-picryl-hydrazyl)自由基清除率测定法研究抗氧化多肽。配制浓度为1×10-5mol/L的DPPH乙醇溶液,避光保存。将2ml,0.1mM的DPPH无水乙醇溶液加入到含有2ml不同酶解样品的洁净试管中,混匀。室温下放置30min后,于517nm处测定吸光度,吸光值越小,表明自由基清除能力越强。
清除率(%)={1-(Ai-Aj)/A0}*100%
式中,A0为2ml,0.1mM的DPPH无水乙醇溶液+2ml的样品试剂,空白对照,Ai为2ml,0.1mM的DPPH无水乙醇溶液+2ml的样品,Aj为2ml的无水乙醇+2ml的样品。
2)ABTS自由基清除活性的测定
以去离子水将ABTS溶解,使ABTS浓度达到7mmol/L,加入过硫酸钾,使过硫酸钾的浓度为2.45nmol/L。之后将该溶液在室温下置于暗处过夜12~16h。将生成的ABTS自由基溶液用磷酸缓冲液(PBS,0.2mol/L,pH 7.4)稀释,使其在734nm下的吸光值为0.70。取0.1ml酶解液与2.9ml ABTS自由基液混合,摇匀30秒钟,暗处反应10分钟,然后在734nm下测定反应液的吸光值。以蒸馏水代替水解液作空白。
清除率(%)=(Ai-Aj)/A0*100%
式中,A0为2.9ml ABTS试剂与0.1ml蒸馏水混合液的吸光值,Aj为2.9ml ABTS+0.1ml的酶解液混合液的吸光值。从图3、4所示黑框蟾蜍抗氧化肽能清除DPPH和ABTS自由基,对ABTS和DPPH自由基清除的EC50分别是3.48μM和3.12μM,并且这种清除能很快发生。自由基氧化在老年痴呆症、帕金森氏症、糖尿病、类风湿性关节炎和肌萎缩性脊髓侧索硬化症引发的神经退行性疾病中有重要作用。黑框蟾蜍抗氧化肽能很好的清除自由基能说明其能应用于自由基氧化导致的相关疾病的治疗。另外,为了防止自由基对皮肤造成的损害,在美容护肤品中添加自由基清除剂比不可少。因此,黑框蟾蜍抗氧化肽也可以应用于美容护肤品中。
Ⅱ、红细胞凝集活性
在96孔血凝板中,初始浓度为3mg/ml的黑框蟾蜍抗氧化肽用25μl PBS倍比稀释,室温静置5-10min,加入75μl 1%鸡红细胞悬液,在4℃静置1h,阳性对照每孔加入75μg/mlodorranalectin,阴性对照孔假如等体积的PBS,观察血凝结果如图5所示,黑框蟾蜍抗氧化肽能凝集红细胞,凝集常数为156.25μg/ml。黑框蟾蜍抗氧化肽具有凝集素样活性,能够凝集红细。凝集素通常能特异性识别哺乳动物细胞表面的糖基序将药物递呈到特定的靶点促进药效,因此他们能作为药物的载体使用。Odorranalectin纳米颗粒对帕金森病的治疗有很好的促进作用。因而从凝集红细胞功能的角度看,黑框蟾蜍抗氧化肽对治疗帕金森病等神经退行性疾病的治疗有很好的促进作用。
Ⅲ、丝氨酸蛋白酶抑制剂活性测定
不同量的黑框蟾蜍抗氧化肽溶解于0.05M Tris-HCl缓冲液与一定量的胰蛋白酶(最终浓度为40μg/ml)于0.05M Tris-HCl缓冲液于室温下保温2min,最后加入发色底物S-2238(终浓度为40μg/ml)启动反应,应用PERKIN ELMER(美国)公司生产的分光光度计于处监测吸收值变化2min,加入同样体积的0.05M Tris-HCl缓冲液与空白对照,抑制常数Ki=[I]/(V0/VI+1)计算。[I]为沼水蛙多功能丝氨酸蛋白酶抑制剂的摩尔浓度,V0为空白对照是胰蛋白酶与发色底物的反应速度,V1为加入黑框蟾蜍抗氧化肽后胰蛋白酶与发色底物的反应速度。此试验重复六次,取平均值。
结果如图6所示,黑框蟾蜍抗氧化肽能很有效地抑制胰蛋白酶的活性,在上述试验条件下抑制半数胰蛋白酶活性所需要的黑框蟾蜍抗氧化肽浓度为2.365μM,对胰蛋白酶的抑制常数Ki是12.1×10-6M。丝氨酸蛋白酶抑制剂对生物体内的生理生化功能都有重要的影响。如,它们在血液凝固、补体形成、纤溶、蛋白质折叠、细胞迁移、细胞分化、细胞基质重建、激素形成及转运、细胞内蛋白质水解、血压调节、肿瘤抑制以及病毒或寄生虫致病性的形成等方面都有重要作用。黑框蟾蜍抗氧化肽能很有效地抑制胰蛋白酶,证实其能在体内调节众多的生理过程和有广泛的临床应用价值。胃炎、胰腺炎的发病过程涉及许多丝氨酸蛋白水解作用,因此抑制这些酶的水解能防止疾病的发生和减低随后的炎症因子对机体造成的损害。具有丝氨酸蛋白酶抑制剂活性的黑框蟾蜍抗氧化肽能应用与炎症相关的胃炎、胰腺炎中。
Claims (1)
1.一种黑框蟾蜍肽在制备作为丝氨酸蛋白酶抑制剂的药物中的用途,所述黑框蟾蜍肽的序列如SEQ ID No.1所示,其第三位半胱氨酸和第八位半胱氨酸形成分子内二硫键。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610917911.XA CN106397564B (zh) | 2016-10-20 | 2016-10-20 | 黑框蟾蜍抗氧化肽及其基因和在制药中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610917911.XA CN106397564B (zh) | 2016-10-20 | 2016-10-20 | 黑框蟾蜍抗氧化肽及其基因和在制药中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN106397564A CN106397564A (zh) | 2017-02-15 |
CN106397564B true CN106397564B (zh) | 2020-07-10 |
Family
ID=58013595
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610917911.XA Expired - Fee Related CN106397564B (zh) | 2016-10-20 | 2016-10-20 | 黑框蟾蜍抗氧化肽及其基因和在制药中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106397564B (zh) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101638432A (zh) * | 2009-03-27 | 2010-02-03 | 中国科学院昆明动物研究所 | 滇蛙抗氧化肽及其基因和应用 |
CN104119434A (zh) * | 2014-07-01 | 2014-10-29 | 昆明理工大学 | 黑眶蟾蜍抗菌肽及其基因和应用 |
CN105037498A (zh) * | 2015-06-19 | 2015-11-11 | 苏州大学 | 源于武夷湍蛙的抗氧化肽及其基因与应用 |
-
2016
- 2016-10-20 CN CN201610917911.XA patent/CN106397564B/zh not_active Expired - Fee Related
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101638432A (zh) * | 2009-03-27 | 2010-02-03 | 中国科学院昆明动物研究所 | 滇蛙抗氧化肽及其基因和应用 |
CN104119434A (zh) * | 2014-07-01 | 2014-10-29 | 昆明理工大学 | 黑眶蟾蜍抗菌肽及其基因和应用 |
CN105037498A (zh) * | 2015-06-19 | 2015-11-11 | 苏州大学 | 源于武夷湍蛙的抗氧化肽及其基因与应用 |
Non-Patent Citations (3)
Title |
---|
Characteristics of cathelicidin-Bg, a novel gene expressed in the ear-side gland of Bufo gargarizans;Gao 等;《Genetics and Molecular Research》;20160805;第15卷(第3期);第5-7页 * |
抗菌肽抗氧化作用机制及其应用前景;肖明珠 等;《食品科学》;20100601;第31卷(第11期);第312页右栏第1段,第314页第3小节 * |
蛙皮抗菌肽促胰岛素分泌功能研究进展;赵茜 等;《生命的化学》;20140415;第34卷(第2期);正文第1段最后一句 * |
Also Published As
Publication number | Publication date |
---|---|
CN106397564A (zh) | 2017-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN107779489B (zh) | 一种具有抗氧化和ace抑制功能的蚕蛹蛋白肽 | |
CN113735966B (zh) | 一种抗肿瘤重组胶原蛋白及其制备方法和应用 | |
CN105131086B (zh) | 一种六肽及其应用 | |
Wang et al. | Identification and molecular cloning of a novel amphibian Bowman Birk-type trypsin inhibitor from the skin of the Hejiang Odorous Frog; Odorrana hejiangensis | |
Chen et al. | Purification and characterization of an antibacterial and anti-inflammatory polypeptide from Arca subcrenata | |
KR20180032588A (ko) | 신규한 트립신 아이소폼 및 이의 용도 | |
AU2020342139B2 (en) | Novel micropeptide HMMW and application thereof | |
CN105566452A (zh) | 一种具有环状结构的抗菌肽及其制备方法和应用 | |
CN106432483B (zh) | 沼水蛙皮肤丝氨酸蛋白酶抑制肽及其基因和制药应用 | |
CN106397564B (zh) | 黑框蟾蜍抗氧化肽及其基因和在制药中的应用 | |
CN106478811B (zh) | 虎纹蛙蛋白酶抑制肽及其基因和在制药中的应用 | |
RU2658781C1 (ru) | Пептид, обладающий противоопухолевой активностью | |
CN113527461B (zh) | 一种马铁菊头蝠来源抗菌肽rf-cath1及其应用 | |
CN107501395B (zh) | 泽陆蛙抗氧化肽及其基因和应用 | |
CN106432425B (zh) | 花姬蛙抗氧化肽及其基因和在制药中的应用 | |
CN101570760B (zh) | 重组鼠β-防御素3多肽及其制备方法与用途 | |
CN100581584C (zh) | 无指盘臭蛙丝氨酸蛋白酶抑制剂及其应用 | |
CN114349821B (zh) | 蛙皮抗氧化肽及其基因在制药和抗皱化妆品的应用 | |
CN113480630A (zh) | 一种长翼蝠来源抗菌肽ms-cath及其应用 | |
CN107098963B (zh) | 一种抑制肿瘤的短肽及其编码基因与应用 | |
CN107513100A (zh) | 虎纹蛙抗菌肽及其基因和应用 | |
TW200825100A (en) | Protein and nucleic acid for glutathione-dependent formaldehyde dehydrogenase (GFD), alcohol dehydrogenase and S-nitrosoglutathione reductase from Antrodia camphorata, manufacturing method and uses therefor | |
CN106432459B (zh) | 花姬蛙抗菌肽及其基因和在制药中的应用 | |
TWI432579B (zh) | 單步驟純化重組胃幽門螺旋桿菌嗜中性白血球激活蛋白(hp-nap)的方法 | |
CN106496317A (zh) | 沼水蛙分泌肽及其基因和在制药中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20200710 |